SG11202104322YA - Trifluoromethyl-substituted sulfonamide as bcl-2-selective inhibitor - Google Patents
Trifluoromethyl-substituted sulfonamide as bcl-2-selective inhibitorInfo
- Publication number
- SG11202104322YA SG11202104322YA SG11202104322YA SG11202104322YA SG11202104322YA SG 11202104322Y A SG11202104322Y A SG 11202104322YA SG 11202104322Y A SG11202104322Y A SG 11202104322YA SG 11202104322Y A SG11202104322Y A SG 11202104322YA SG 11202104322Y A SG11202104322Y A SG 11202104322YA
- Authority
- SG
- Singapore
- Prior art keywords
- bcl
- trifluoromethyl
- selective inhibitor
- substituted sulfonamide
- sulfonamide
- Prior art date
Links
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 title 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 title 1
- 229940124639 Selective inhibitor Drugs 0.000 title 1
- -1 Trifluoromethyl-substituted sulfonamide Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811268572 | 2018-10-29 | ||
| CN201910249783 | 2019-03-29 | ||
| CN201910933513 | 2019-09-29 | ||
| PCT/CN2019/113963 WO2020088442A1 (en) | 2018-10-29 | 2019-10-29 | Trifluoromethyl-substituted sulfonamide as bcl-2-selective inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202104322YA true SG11202104322YA (en) | 2021-05-28 |
Family
ID=70462524
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202104322YA SG11202104322YA (en) | 2018-10-29 | 2019-10-29 | Trifluoromethyl-substituted sulfonamide as bcl-2-selective inhibitor |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20220002290A1 (en) |
| EP (1) | EP3858832A4 (en) |
| JP (1) | JP7473545B2 (en) |
| KR (1) | KR20210086680A (en) |
| CN (2) | CN112888687B (en) |
| AU (1) | AU2019372640B2 (en) |
| BR (1) | BR112021008323A2 (en) |
| CA (1) | CA3117849A1 (en) |
| IL (1) | IL282632B2 (en) |
| MX (2) | MX2021004856A (en) |
| PH (1) | PH12021550958A1 (en) |
| SG (1) | SG11202104322YA (en) |
| WO (1) | WO2020088442A1 (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7558977B2 (en) * | 2019-05-24 | 2024-10-01 | チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド | Selective BCL-2 inhibitors based on disubstituted sulfamides containing methyl and trifluoromethyl groups |
| EP4129998A4 (en) * | 2020-04-29 | 2024-05-01 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Crystal of trifluoromethyl/chloro disubstituted sulfonamide selective bcl-2 inhibitor |
| JP2024504542A (en) * | 2021-02-01 | 2024-02-01 | アセンテージ ファーマ（スーチョウ）カンパニー，リミティド | Sulfonylbenzamide derivatives as BCL-2 inhibitors |
| MX2023011000A (en) * | 2021-03-19 | 2023-09-28 | Eil Therapeutics Inc | COMPOUNDS CONTAINING ((3-NITROPHENYL)SULPHONYL)ACETAMIDE AS BCL-2 INHIBITORS. |
| WO2022253313A1 (en) | 2021-06-04 | 2022-12-08 | 正大天晴药业集团股份有限公司 | Phosphate of trifluoromethyl-substituted sulfonamide compound |
| CN119768402A (en) * | 2022-07-12 | 2025-04-04 | 正大天晴药业集团股份有限公司 | Trifluoromethyl group-containing compound |
| WO2024032776A1 (en) * | 2022-08-12 | 2024-02-15 | Fochon Biosciences, Ltd. | Compounds as bcl-2 inhibitors |
| CN115260191B (en) * | 2022-09-29 | 2022-12-27 | 上海睿跃生物科技有限公司 | Piperidine compound and preparation method and application thereof |
| WO2024217552A1 (en) * | 2023-04-20 | 2024-10-24 | 正大天晴药业集团股份有限公司 | Use of trifluoromethyl-containing compound in treatment of hematological tumors |
| WO2025124487A1 (en) * | 2023-12-12 | 2025-06-19 | 正大天晴药业集团股份有限公司 | Combination of trifluoromethyl-containing compound and furan-containing pyrrole compound for use in treating blood tumors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA108193C2 (en) * | 2008-12-04 | 2015-04-10 | APOPTOZINDUCE FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTO-IMMUNE DISEASES | |
| MX363470B (en) * | 2008-12-05 | 2019-03-25 | Abbvie Inc | Sulfonamide derivatives as bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases. |
| MY155645A (en) * | 2009-05-26 | 2015-11-13 | Abbvie Bahamas Ltd | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| NZ708508A (en) | 2010-11-23 | 2016-06-24 | Abbvie Bahamas Ltd | Methods of treatment using selective bcl-2 inhibitors |
| US20140275082A1 (en) * | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| CN109641897B (en) * | 2016-09-01 | 2021-12-07 | 北京赛林泰医药技术有限公司 | Bcl-2 selective inhibitors, their preparation and use |
-
2019
- 2019-10-29 CN CN201980067260.1A patent/CN112888687B/en active Active
- 2019-10-29 JP JP2021523829A patent/JP7473545B2/en active Active
- 2019-10-29 IL IL282632A patent/IL282632B2/en unknown
- 2019-10-29 BR BR112021008323-5A patent/BR112021008323A2/en unknown
- 2019-10-29 MX MX2021004856A patent/MX2021004856A/en unknown
- 2019-10-29 CA CA3117849A patent/CA3117849A1/en active Pending
- 2019-10-29 US US17/289,406 patent/US20220002290A1/en active Pending
- 2019-10-29 EP EP19878278.1A patent/EP3858832A4/en active Pending
- 2019-10-29 KR KR1020217016174A patent/KR20210086680A/en active Pending
- 2019-10-29 WO PCT/CN2019/113963 patent/WO2020088442A1/en active IP Right Grant
- 2019-10-29 CN CN202310104396.3A patent/CN116199686A/en active Pending
- 2019-10-29 SG SG11202104322YA patent/SG11202104322YA/en unknown
- 2019-10-29 AU AU2019372640A patent/AU2019372640B2/en active Active
-
2021
- 2021-04-27 MX MX2024008886A patent/MX2024008886A/en unknown
- 2021-04-28 PH PH12021550958A patent/PH12021550958A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020088442A1 (en) | 2020-05-07 |
| JP7473545B2 (en) | 2024-04-23 |
| CA3117849A1 (en) | 2020-05-07 |
| PH12021550958A1 (en) | 2021-11-29 |
| MX2024008886A (en) | 2024-09-17 |
| IL282632A (en) | 2021-06-30 |
| EP3858832A4 (en) | 2022-06-08 |
| CN112888687A (en) | 2021-06-01 |
| EP3858832A1 (en) | 2021-08-04 |
| CN112888687B (en) | 2023-01-24 |
| US20220002290A1 (en) | 2022-01-06 |
| AU2019372640A1 (en) | 2021-06-03 |
| JP2022506442A (en) | 2022-01-17 |
| BR112021008323A2 (en) | 2021-08-03 |
| IL282632B2 (en) | 2024-06-01 |
| AU2019372640B2 (en) | 2022-08-04 |
| MX2021004856A (en) | 2021-10-13 |
| KR20210086680A (en) | 2021-07-08 |
| IL282632B1 (en) | 2024-02-01 |
| CN116199686A (en) | 2023-06-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL282632A (en) | Trifluoromethyl-substituted sulfonamide as bcl-2-selective inhibitor | |
| IL276594A (en) | Fap inhibitor | |
| IL273786A (en) | Novel sulfonamide carboxamide compounds | |
| IL272555A (en) | Novel sulfonamide carboxamide compounds | |
| IL272550A (en) | Novel sulfonamide carboxamide compounds | |
| IL271716A (en) | Novel sulfonamide carboxamide compounds | |
| IL277006A (en) | Cd73 inhibitors | |
| GB201705971D0 (en) | Inhibitor compounds | |
| IL304348A (en) | Cd73 inhibitors | |
| EP3447058A4 (en) | Novel broad-spectrum -lactamase inhibitor | |
| GB201819126D0 (en) | Inhibitor compounds | |
| IL275532A (en) | Mtor inhibitor compounds | |
| IL275531A (en) | Mtor inhibitor compounds | |
| GB201809939D0 (en) | Eastase inhibitor | |
| GB201819136D0 (en) | Inhibitor compounds | |
| GB201806131D0 (en) | Inhibitor compounds | |
| GB201806130D0 (en) | Inhibitor compounds | |
| GB201806132D0 (en) | Inhibitor coumpounds | |
| GB201720145D0 (en) | Inhibitor compounds | |
| GB201708502D0 (en) | Inhibitor compounds | |
| GB201708507D0 (en) | Inhibitor compounds | |
| GB201708510D0 (en) | Inhibitor compounds | |
| GB201705968D0 (en) | Inhibitor compounds | |
| GB201708999D0 (en) | Recrystallization Inhibitor | |
| GB201621619D0 (en) | Inhibitor compounds |